

This is the author-created version of the following work:

Hall, Leanne M., Ediriweera, Yashodha, Banks, Jennifer, Nambiar, Anjali, and Heal, Clare (2020) *Cooling to reduce the pain associated with vaccination: a systematic review*. *Vaccine*, 38 (51) pp. 8082-8089.

Access to this file is available from:

<https://researchonline.jcu.edu.au/65970/>

Published Version: (C) 2020 Elsevier Ltd. All rights reserved, Accepted Version: Open Access in an Institutional Repository under a CC BY-NC-ND license after an embargo of 12 months.

Please refer to the original source for the final version of this work:

<https://doi.org/10.1016/j.vaccine.2020.11.005>

Cooling to reduce pain associated with vaccination: a systematic review

Abstract

Background: Vaccine injections are the most common cause of iatrogenic pain in childhood and a cause of anxiety in adulthood. Skin cooling techniques, including icepacks and vapocoolants, may provide pain relief during intramuscular injections.

Objective: To identify the effects of skin cooling techniques on pain associated with immunisation.

Methods: MEDLINE (Ovid), CINAHL, EMCARE, INFORMIT and Scopus were searched for randomised controlled trials (RCTs) investigating the use of skin cooling techniques on pain associated with vaccination. Study and intervention details, outcomes measures and results were extracted and risk of bias assessed using the Cochrane Risk of Bias tool. Due to heterogeneity of studies, a narrative synthesis was performed.

Results: Thirteen trials were included, involving 689 paediatric and 829 adult participants. All studies used vapocoolant or ice as one of the interventions. Comparator groups included topical EMLA cream, breastfeeding, distraction techniques and tactile stimulation. Vapocoolant reduced vaccination-related pain in all adult studies and six paediatric studies however the use of ice packs in paediatric patients was not effective.

Conclusion: The use of cooling techniques reduces pain associated with vaccinations in adults. Paediatric studies show mixed results for vapocoolants and an inability for ice to decrease vaccine-injection pain. Larger RCTs are required to determine the most effective administration techniques and optimise the analgesic effects of skin cooling.

Keywords: Pain, vaccination, immunisation, vapocoolant, ice, cooling

27 Introduction

28 Vaccine injections are the most common cause of iatrogenic pain in childhood(1) and
29 anxiety in up to 90% of adults (2). Injection-associated pain and anxiety is a contributing
30 factor to future non-compliance with scheduled vaccinations throughout the lifespan (3,4).
31 Vaccinations are heralded as saving up to 3 million lives each year (5) and are the
32 cornerstone of herd immunity, therefore interventions to reduce the pain and anxiety of
33 intra-muscular vaccinations, and consequently reduced immunisation rates, warrant further
34 investigation (6). A study of an adult working population found that 97% of participants
35 chose to receive intranasal influenza vaccine over its injectable equivalent, with 14% citing
36 fear of injections as the primary reason for choosing the intranasal route of administration
37 (7). Pain associated with immunisation is now recognised as a significant adverse event, and
38 adequate pain management strategies should therefore be incorporated into every
39 vaccination (8).

40 Previous systematic and literature reviews in paediatric populations (9,10) and combined
41 paediatric and adult populations (11), have investigated interventions to reduce the pain of
42 immunisation. Topical analgesics were found to be effective in both adult (11) and
43 paediatric populations (9,10), as were sucrose solutions, breastfeeding in the 0-2 year age
44 group (9) and cooling combined with vibration(10) however cooling alone has yielded mixed
45 results.

46 Cold therapy has been used for centuries to mitigate pain (12). Pain reduction begins at the
47 threshold of 10⁰C and continues to increase as skin temperature approaches 0⁰C (13). The
48 analgesic effect of vapocoolant sprays and ice-packs is further enhanced by their ability to
49 suppress the autonomic responses by decreasing skin conduction level and blood flow (14).
50 In addition to these effects, cooling techniques are considered to be cost-effective and have
51 few, if any, side effects when applied correctly (2).

52 This review aims to identify and synthesise randomised controlled trials (RCTs) investigating
53 the use of ice or vapocoolant spray to reduce the pain of immunisation in paediatric and
54 adult populations.

55

56 [Materials and methods](#)

57 This study was prospectively registered with the International Prospective Register of
58 Systematic Reviews (PROSPERO) (CRD42020140084) and guided by the 'Preferred Reporting
59 Items for Systematic Reviews and Meta-Analyses' (PRISMA) guideline (15).

60 [Literature search](#)

61 A comprehensive literature search, developed in consultation with the Cochrane
62 Collaboration guidelines (16), of the MEDLINE (Ovid), CINAHL, EMCARE, INFORMIT and
63 Scopus databases was conducted on 24th May 2019. . The search strategy included MeSH
64 terms and key words related to the intervention: "immunisation", "vaccinations",
65 "injections", "cold therapy", "ice packs" and "vapocoolant". These search terms were
66 adapted for use with each bibliographic database in combination with database-specific
67 filters. The search was restricted to studies published in the English language. A final search
68 of the databases was conducted on 23rd August 2019 prior to final data analysis.

69 All articles identified by search were independently screened for eligibility by two reviewers
70 (YE and LH). Bibliographies of included studies were hand-searched for additional articles
71 meeting the selection criteria. Discrepancies between reviewers were resolved by an
72 independent third reviewer (CH).

73 [Selection criteria](#)

74 Randomised controlled trials that investigated the use of cold techniques (e.g. ice-packs,
75 vapocoolants) in people undergoing vaccine injections in any setting (e.g. hospital or
76 community) were included. No restrictions were placed on the age of participants. Studies
77 of needle-related procedures other than vaccine injections (e.g. venepuncture and venous
78 cannulation) were excluded.

79 [Data extraction and quality assessment](#)

80 Data from included studies were independently extracted into standardised spreadsheets
81 by two reviewers (YE and LH) and compared for accuracy. Discrepancies were resolved by a
82 third reviewer (CH). The following data were tabulated: author name and year, study setting
83 and design, participant characteristics, interventions and outcome measures used, results
84 and key conclusions.

85 The methodological quality of included studies was independently assessed by two
86 reviewers (YE and AN) using the Cochrane risk-of-bias tool for RCTs (The Cochrane
87 Collaboration) (16). Disagreements were resolved by a third reviewer (CH). Studies were
88 categorised as low risk of bias if all seven domains were rated as low risk; unclear risk of bias
89 if any domains were rated as unclear; and high risk of bias if one or more domains were
90 rated as high risk.

91 Outcome measures

92 The primary outcome measure was pain associated with vaccination, measured using self-
93 reported pain scales, parent-reported pain scales, infant crying time or infant behaviour
94 scales. A meta-analysis was not possible due to the small sample size, heterogeneity of data
95 and the lack of equivalent comparator groups across studies. Consequently, a narrative
96 synthesis of the data was conducted.

97

98 Results

99 The search strategy identified 428 studies of potential relevance. After duplicates were
100 removed, 404 studies were screened by title and abstract and 13 full texts assessed for
101 eligibility. Four additional studies were included after manual reference searches (Figure 1).
102 Ten studies involving paediatric participants (n=689) and three involving adult (> 18 years of
103 age) participants (n=829) undergoing vaccination were included in this review. The majority
104 of trials were conducted in the United States of America (n=8) and Canada (n=2) (Table 1).
105 All studies used ice or vapocoolant as an intervention. The comparator groups were usual
106 care/no intervention (17-23) and/or various physical and pharmacological interventions.
107 These included distraction methods (17,24,25), topical anaesthetic cream (24-26),
108 breastfeeding (21,26), cold saline (2), compressed air (22,27,28), and tactile stimulation (25).
109 The number of vaccinations administered during trials ranged from one to six successive
110 injections. Sample sizes tended to be smaller in the paediatric studies than adult studies,
111 with all except Boroumandfar *et al* having less than 100 participants.

112 Studies conducted in paediatric populations

113 Paediatric studies included infants and children up to 18 years of age, three of which
114 investigated use of cooling techniques with injection of various vaccines, most commonly

115 diphtheria-tetanus-pertussis vaccine (acellular and whole-cell forms) (19,21-24,26-28)
116 (Table 1). Other vaccinations included measles-mumps-rubella (23), Hepatitis B (21) and
117 tetanus (20). Ice was used as the skin cooling technique in two paediatric studies (19,20),
118 the remaining using vapocoolant either sprayed directly onto the skin (17,21,26-28) or
119 applied via vapocoolant-soaked cotton balls (22-24) in an attempt to control for the
120 potential confounding effect of the spray being perceived as a noxious stimulus.

121 **Ice**

122 Both studies that assessed the efficacy of ice in reducing pain associated with vaccination
123 found it was ineffective. Self-reported pain levels (Faces Pain rating scale) did not differ with
124 the application of ice for 15 minutes prior to injection of the tetanus vaccine in children
125 aged 10 to 18 years in the study by Ebner *et al* (20). Application of ice for 30 seconds in the
126 study by Gedaly-Duff and Burns(19) made no difference to pain levels as reported by both
127 the children participating (using the Wong-Baker Faces and Oucher scales) or the observer
128 (using the Global Mood Scale and pulse rate).

129 **Vapocoolant**

130 Five trials showed efficacy of vapocoolant sprays in reducing vaccination pain or distress.
131 Vapocoolant spray and compressed air both reduced pain of vaccination in children aged
132 four to 6 years compared to no intervention (22). From this, Abbott and Fowler (22)
133 concluded that cognitive processes altered pain processing and associated responses such
134 that the placebo intervention was equally as effective as the intervention itself.

135 Boroudmandfar *et al* (21) concluded from observer assessment using the Neonatal Infant
136 pain scale that both cooling and breastfeeding were superior to usual care in reducing pain
137 but breastfeeding was most effective. In a 2 X 2 factorial design that involved vapocoolant
138 spray or compressed air with or without cognitive information, Eland (28) reported reduced
139 pain levels with vapocoolant regardless of the information provided about the intervention
140 and, in contrast to Abbott and Fowler (22), that vapocoolant was more effective at reducing
141 pain than a placebo air spray.

142 Cohen Reiss *et al* demonstrated that vapocoolant spray (combined with distraction) reduced
143 distress, pain VAS and cry time immediately post-vaccination compared with the distraction-
144 control group (24), however differences in distress were not maintained five minutes post-

145 injection. No difference was found between vapocoolant spray and EMLA cream. Maikler *et*
146 *al* reported that vapocoolant spray did not reduce cry duration compared to compressed air
147 but cry latency and distress behaviours at the time of injection were reduced (27).

148 Three vapocoolant studies found no efficacy for this cooling technique to reduce vaccination
149 pain in the paediatric population. Pain and distress during vaccination, as assessed using
150 self-, carer- and observer-measures, did not differ between vapocoolant and usual care in
151 children aged four to six years in the study by Cohen *et al* (23). Similarly, Gupta found no
152 evidence of efficacy of vapocoolant sprays post-vaccination (26). These authors concluded
153 that the addition of topical EMLA or vapocoolant spray to breastfeeding does not decrease
154 the duration of cry immediately post-vaccination but both interventions reduced Neonatal
155 Infant Pain Scale scores at one and three minutes after injection (26). The study by Luthy *et*
156 *al* relied on parental perceptions of their child's pain and anxiety post-vaccination (17). In
157 contrast to Cohen Reis *et al* vapocoolant spray was shown to be no more effective than
158 distraction techniques (watching a DVD) or usual care (17).

159 [Studies conducted in adult populations](#)

160 **Ice**

161 Of the three studies investigating cooling techniques in adults, only one incorporated ice as
162 one of the intervention arms (18). Ice applied to the skin for 30 seconds was shown to
163 reduce pain during needle insertion and administration of the tetanus vaccine compared to
164 usual care (no treatment) in the study by Akcimen *et al* (18). There was no difference in pain
165 VAS between ice and vapocoolant spray (a second intervention arm of this study) at the
166 time of needle insertion however scores were significantly lower in the ice group when the
167 vaccine was introduced.

168 **Vapocoolant**

169 All three adult studies used vapocoolant as an intervention.

170 Akcimen *et al* (18) reported effectiveness of vapocoolant sprayed directly onto the skin in
171 reducing pain compared to usual care at the time of needle insertion, however pain levels
172 were significantly higher with introduction of tetanus vaccine.

173

174 Mawhorter *et al* demonstrated a decrease in pain immediately post-vaccination with the
175 application of vapocoolant to the skin via a cotton ball compared to cold saline (4°C) (2). The
176 difference in pain between the two groups was not evident five minutes post-injection.
177 Taddio *et al* provided a comparison of vapocoolant spray (applied directly to the skin) to
178 topical anaesthetic (liposomal lidocaine), tactile stimulation and distraction (reading a
179 magazine) (25) that revealed no efficacy for the cooling technique however topical
180 anaesthetic reduced self-perceived pain compared to distraction. Whilst using vapocoolant
181 spray as one of the group allocations, the primary aim of the study by Taddio *et al* was to
182 determine the effectiveness of topical anaesthesia compared to vapocoolant spray, tactile
183 stimulation and distraction. The effectiveness of vapocoolant and topical anaesthesia did
184 not differ but no summary statistics were provided to allow comparison of vapocoolant to
185 tactile stimulation and distraction.

186

187 Risk of bias

188 Three studies were considered at high risk of bias, two due to lack of or inadequate blinding
189 of participants (17,18) and one due to potential selection bias (20). All other included
190 studies were considered to be at unclear risk of bias (Figure 2).

191 Discussion

192 Thirteen studies that investigated the efficacy of skin cooling techniques in reducing pain
193 associated with vaccinations in adults and children were reviewed. Adult studies more
194 consistently demonstrated a reduction in pain with skin cooling interventions compared to
195 those in the paediatric population. Potential reasons for this include differences in: outcome
196 measures and participant age, comparator groups, vaccine/s administered and application
197 of the cooling technique. Each of these are discussed below.

198 Outcome measures and participant age

199 The subjective nature of pain makes it difficult to measure and often relies on gold standard
200 self-reporting of pain levels using validated instruments e.g. visual analogue scale (VAS).
201 Self-reported scales are not considered applicable to children less than three years of
202 age(29) therefore this difficulty is compounded in infants and young children. As such
203 surrogate measures are used based commonly on behavioural and physiological changes.

204 Adult studies in this review relied on self-reported pain using Pain VAS and McGill Present
205 Pain Intensity, both of which have been validated (30,31). Paediatric studies relied on
206 several different outcome measures which varied depending on participant age. Luthy *et al*
207 used parental perception of their child's pain, despite including participants from two to 12
208 years of age (17). Potential differences in surrogate reports of pain by parents and those the
209 children, as demonstrated by Abbott and Fowler (22), may have self-reported could have
210 contributed to the lack of efficacy of vapocoolant in this study.

211 **Comparator groups**

212 Not all studies utilised a usual care or no-intervention control group, instead opting to either
213 use a combined intervention in which one component was carried through all comparator
214 groups (e.g. vapocoolant+distraction, EMLA cream+distraction and distraction alone (24)),
215 or a control group that closely resembles the intervention (e.g. vapocoolant spray and
216 compressed air (27)). In each of these cases, the effect of cooling may be mitigated by the
217 effect of the common or comparator intervention. Gupta *et al* used breastfeeding as an
218 intervention common to each randomised group, however breastfeeding alone has been
219 shown to be effective in reducing pain associated with vaccination (11). It is possible that
220 non-pharmacological interventions act like a filter (e.g. breastfeeding) in which a certain
221 level of pain passes through but higher pain is attenuated. Although additional filters may
222 be added (for example breastfeeding+vapocoolant) the effect of combined filters may be
223 synergistic and therefore the reduction in pain may not be proportional to the effect of
224 each individual intervention filters.

225 In a similar manner, Ebner conducted her study in a cohort of children receiving tetanus
226 vaccinations in an emergency department after presentation with wounds that potentially
227 required suturing (20). Attention influences the spinal gating mechanism that modulates
228 pain (32). Depending on the severity of the wound, it could garner more attention than the
229 vaccination, in which case the potential analgesic effect of ice may have been diminished by
230 the distraction of the wound itself.

231 **Vaccine/s administered**

232 The pain or discomfort from the injections is the combined result of local tissue injury from
233 the needle insertion and the introduction of the vaccine, which increases intra-tissue

234 pressure as the volume increases. Thus, higher volumes of vaccines may cause more pain at
235 the injection site than lower volumes. Different vaccinations may also be perceived as more
236 painful than others. For example, Burns et al showed that pain scores for Human Papilloma
237 Virus vaccination were higher than Hepatitis A and meningococcal vaccinations(33). Studies
238 in children receiving the DPT vaccine showed vapocoolant was effective (either immediately
239 or within 3 minutes of injection) in reducing pain levels.

240 The number of vaccinations administered differed between trials. All studies that used
241 vapocoolant in infants and children who received two or less vaccines in the one
242 consultation reported positive effects of cooling either immediately (21,22,24,27,28) or
243 post-vaccination (26). Those that allowed for multiple injections (17,23) had less favourable
244 outcomes. This did not hold true in single-injection paediatric studies that used an ice
245 intervention. The order of injection of multiple vaccinations can affect the pain response in
246 infants given the first injection may focus attention and stimulate pain-processing
247 mechanisms that intensify subsequent signals (34). Neither study that allowed for multiple
248 vaccinations stated if the order of vaccine administration was randomised.

249 [Application of cooling techniques](#)

250 Any intervention applied prior to injection could focus participant's attention on the site to
251 which it is applied and heighten the pain response. Vapocoolants cause cold and often
252 burning sensations of the skin that can be perceived as noxious stimuli, increasing distress
253 and anxiety (23) and potentially mitigating any benefit from their application. Eight studies
254 across the lifespan demonstrated a benefit of vapocoolants in reducing vaccination pain,
255 therefore this is unlikely to explain the inconsistent results.

256 There appears to be little consensus on the most effective technique to apply cooling
257 interventions. This review identified studies that applied ice for as little as 30 s (18,19) or up
258 to 15 minutes (20). The time for which vapocoolants were applied was less variable (2-10 s
259 when sprayed directly onto the skin and 10-20 s when applied via soaked cotton balls) and
260 reflects the potential for these volatile liquids to cause skin freezing. These differences in
261 the technique used in applying the intervention do not account for the variable results. Both
262 paediatric studies that used ice as an intervention showed no difference in pain levels
263 compared to usual care despite the short and long durations of application. Similarly,

264 studies in similar aged participants that used soaked cotton balls as a vehicle for
265 vapocoolants had contradicting results (22,23).

266 Limitations

267 The methodological heterogeneity of the included trials in terms of sample size,
268 intervention, comparator groups and measured outcomes meant a meaningful meta-
269 analysis could not be performed. Additionally, although there were 10 paediatric studies,
270 compared to three in the adult population, their numbers contributed to only 45% of total
271 participants studied, indicating a need for larger scale RCTs in this group.

272 Another limitation of this review is that all studies were considered to be either at unclear
273 (n=10) or high risk of bias (Figure 2), commonly due to performance and reporting biases.
274 The results of this review should therefore be interpreted with caution.

275 The effectiveness of vapocoolant in the study by Taddio *et al* (25) was difficult to determine
276 as it was compared to other interventions without a usual care or no-intervention control.
277 The remaining two studies (2,18) suggest that skin cooling using vapocoolant sprays can be
278 recommended as a form of analgesia to reduce pain associated with vaccine injections in
279 adults. Ice shows promise in mitigating immediate vaccination-related pain (18) but further
280 research is required to replicate these findings.

281 Clinical implications

282 Further research is needed to assess the effectiveness of skin cooling techniques,
283 particularly in infants and children, as a viable method of reducing immunisation pain.
284 However, based on current evidence, the use of vapocoolant sprays in adults can
285 successfully be implemented in primary healthcare settings. Both ice and vapocoolant have
286 few adverse effects, are cost effective and can be easily applied to injection sites.
287 Vapocoolants have the advantage of providing instantaneous cooling effects to the skin,
288 increasing efficiency while ice has widespread availability with minimal cost.

289 Conclusions

290 The use of skin cooling techniques may effectively reduce the pain associated with vaccine-
291 injections. Whilst paediatric study findings are inconclusive, this review concludes that the
292 use of vapocoolant spray and ice in adults can successfully decrease pain associated with
293 vaccination. More rigorous and larger-scale RCT study designs are needed to determine the

294 effectiveness and applicability of skin cooling techniques for reducing immunisation pain in
295 primary healthcare settings. These should aim to determine to what extent pain mitigation
296 is dependent on the nature of the intervention, the specific vaccine, and age group of
297 participants.

298

299 [Acknowledgements](#)

300 The authors would like to thank Mr Stephen Anderson, medical librarian, James Cook
301 University, for his assistance with this systematic review.

302 [Funding](#)

303 Nil

304 [Conflict of interest statements](#)

305 None of the authors have any conflict of interests to declare.

306 References

- 307 1. Schechter, N.L., et al., *Pain reduction during pediatric immunizations: evidence-based*
308 *review and recommendations*. Pediatrics, 2007. **119**(5): p. e1184-98.
- 309 2. Mawhorter, S., et al., *Topical vapocoolant quickly and effectively reduces vaccine-*
310 *associated pain: results of a randomized, single-blinded, placebo-controlled study*. J
311 Travel Med, 2004. **11**(5): p. 267-72.
- 312 3. Nir, Y., et al., *Fear of injections in young adults: prevalence and associations*. Am J
313 Trop Med Hyg, 2003. **68**(3): p. 341-4.
- 314 4. Taddio, A., et al., *From the mouth of babes: Getting vaccinated doesn't have to hurt*.
315 Can J Infect Dis Med Microbiol, 2014. **25**(4): p. 196-200.
- 316 5. Organization, W.H. *Immunization coverage*. [Internet] 2019 [cited 2020 15 March];
317 Available from: [https://www.who.int/news-room/fact-sheets/detail/immunization-](https://www.who.int/news-room/fact-sheets/detail/immunization-coverage)
318 [coverage](https://www.who.int/news-room/fact-sheets/detail/immunization-coverage).
- 319 6. Organization, W.H., *Weekly epidemiological record*. 2014: Switzerland. p. 561-576.
- 320 7. Sendi, P., et al., *Intranasal influenza vaccine in a working population*. Clin Infect Dis,
321 2004. **38**(7): p. 974-80.
- 322 8. Gidudu, J.F., et al., *Immunization site pain: case definition and guidelines for*
323 *collection, analysis, and presentation of immunization safety data*. Vaccine, 2012.
324 **30**(30): p. 4558-77.
- 325 9. Shah, V., A. Taddio, and M.J. Rieder, *Effectiveness and tolerability of pharmacologic*
326 *and combined interventions for reducing injection pain during routine childhood*
327 *immunizations: Systematic review and meta-analyses*. Clinical Therapeutics, 2009.
328 **31**(SUPPL. 2): p. S104-S151.
- 329 10. Lee, V.Y., et al., *Improving vaccine-related pain, distress or fear in healthy children*
330 *and adolescents-a systematic search of patient-focused interventions*. Hum Vaccin
331 Immunother, 2018. **14**(11): p. 2737-2747.
- 332 11. Shah, V., et al., *Pharmacological and Combined Interventions to Reduce Vaccine*
333 *Injection Pain in Children and Adults: Systematic Review and Meta-Analysis*. Clin J
334 Pain, 2015. **31**(10 Suppl): p. S38-63.
- 335 12. Auerbach, P., *Physical methods for treatment of pain*, in *Wilderness Medicine*,
336 Mosby, Editor. 2007, An Imprint of Elsevier.
- 337 13. Travell, J., *Factors affecting pain of injection*. J Am Med Assoc, 1955. **158**(5): p. 368-
338 71.
- 339 14. Saeki, Y., *Effect of local application of cold or heat for relief of pricking pain*. Nurs
340 Health Sci, 2002. **4**(3): p. 97-105.
- 341 15. Moher D, L.A., Tetzlaff J, Althman D G, Group P, *Preferred reporting items for*
342 *systematic reviews and meta-analyses: the PRISMA statement*. J Clin Epidemiol,
343 2009. **62**(10): p. 1006- 1012.
- 344 16. Higgins, J.P., et al., *The Cochrane Collaboration's tool for assessing risk of bias in*
345 *randomised trials*. BMJ, 2011. **343**: p. d5928.

- 346 17. Luthy, K.E., R.L. Beckstrand, and A. Pulsipher, *Evaluation of methods to relieve*
347 *parental perceptions of vaccine-associated pain and anxiety in children: a pilot study.*
348 *Journal of Pediatric Health Care*, 2013. **27**(5): p. 351-8.
- 349 18. Akcimen, M., C. Bedel, and F. Selvi, *Application of ice and vapocoolant spray to*
350 *reduce tetanus vaccine pain: A prospective, randomized, controlled, clinical study.*
351 *Annals of Medical Research*, 2019. **26**(6).
- 352 19. Gedaly-Duff, V. and C. Burns, *Reducing children's pain-distress associated with*
353 *injections using cold: a pilot study.* *J Am Acad Nurse Pract*, 1992. **4**(3): p. 95-100.
- 354 20. Ebner, C.A., *Cold therapy and its effect on procedural pain in children.* *Issues Compr*
355 *Pediatr Nurs*, 1996. **19**(3): p. 197-208.
- 356 21. Boroumandfar, K., et al., *Comparison of vaccination-related pain in infants who*
357 *receive vapocoolant spray and breastfeeding during injection.* *Iran J Nurs Midwifery*
358 *Res*, 2013. **18**(1): p. 33-7.
- 359 22. Abbott, K. and S. Fowler-Kerry, *The use of a topical refrigerant anesthetic to reduce*
360 *injection pain in children.* *J Pain Symptom Manage*, 1995. **10**(8): p. 584-90.
- 361 23. Cohen, L.L., et al., *A randomized controlled trial of vapocoolant for pediatric*
362 *immunization distress relief.* *Clin J Pain*, 2009. **25**(6): p. 490-4.
- 363 24. Cohen Reis, E. and R. Holubkov, *Vapocoolant spray is equally effective as EMLA*
364 *cream in reducing immunization pain in school-aged children.* *Pediatrics*, 1997.
365 **100**(6): p. E5.
- 366 25. Taddio, A., et al., *A randomized controlled trial of analgesia during vaccination in*
367 *adults.* *Vaccine*, 2010. **28**(32): p. 5365-9.
- 368 26. Gupta, N.K., et al., *Randomized controlled trial of topical EMLA and vapocoolant*
369 *spray for reducing pain during wDPT vaccination.* *World J Pediatr*, 2017. **13**(3): p.
370 236-241.
- 371 27. Maikler, V.E., *Effects of a skin refrigerant/anesthetic and age on the pain responses*
372 *of infants receiving immunizations.* *Res Nurs Health*, 1991. **14**(6): p. 397-403.
- 373 28. Eland, J.M., *Minimizing pain associated with prekindergarten intramuscular*
374 *injections.* *Issues Compr Pediatr Nurs*, 1981. **5**(5-6): p. 361-72.
- 375 29. Mathew, P.J. and J.L. Mathew, *Assessment and management of pain in infants.*
376 *Postgrad Med J*, 2003. **79**(934): p. 438-43.
- 377 30. Melzack, R., *The McGill Pain Questionnaire: major properties and scoring methods.*
378 *Pain*, 1975. **1**(3): p. 277-99.
- 379 31. Su, L., et al., *Measuring injection-site pain associated with vaccine administration in*
380 *adults: a randomised, double-blind, placebo-controlled clinical trial.* *J Epidemiol*
381 *Biostat*, 2000. **5**(6): p. 359-65.
- 382 32. Melzack, R. and P.D. Wall, *Pain Mechanisms: A New Theory.* *Science*, 1965.
383 **150**(3699): p. 971-979.
- 384 33. Joseph Burns, J., et al., *A Blinded Comparison of Injection Pain With Quadrivalent*
385 *Human Papilloma Virus Vaccine Versus Other Vaccines.* *J Pediatric Infect Dis Soc*,
386 2015. **4**(4): p. 396-7.

- 387 34. Ipp, M., et al., *Order of Vaccine Injection and Infant Pain Response*. Archives of
388 Pediatrics & Adolescent Medicine, 2009. **163**(5): p. 469-472.
389
390

391 **Figure 1:** PRISMA flow diagram

392 **Figure 2:** Summary of risk of bias - Author's assessment of methodological quality of
393 individual studies. Low risk in green (+), unclear risk in yellow (?), high risk in red (-).

394

395

396

397 **Table 1:** Details of studies included in narrative review

398

First author, year, country	Participant age	Vaccine and injection details [number of vaccinations received]	Cooling Intervention	How cooling applied to skin (application time)	Comparator group	Outcome measures (reported by)	Results (cooling intervention compared to comparator group/s)
PEDIATRIC STUDIES							
Abbott 1995 Canada (22)	4-5.5 y (n=90)	DPT; IM; deltoid muscle - needle gauge and volume of injectable solution constant but length of needle and injection technique varied [1]	Refrigerant topical anesthetic spray (Fluroethyl) (n=30)	Soaked cotton ball (10 s)	1) Placebo topical spray (compressed air + Freon) via sterile cotton ball for 10 s (n=30); 2) No-treatment control (n=30)	Pain VAS (child); Anxiety and expected pain VAS (parent)	1) No difference 2) Anesthetic spray reduced pain compared to no-treatment control
Boroumandfar 2013 Iran (21)	<6mo (n=144)	Hepatitis B (35%) and DTP (65%); injection details NR [2]	Vapocoolant spray (n=48)	Directly to injection site (1-3 s from 15 cm away)	1) Breastfeeding (n=48) 2) No-treatment control (n=48)	Neonatal infant pain scale (NIPS) 2 pain assessment checklist (researcher)	1) Frequency of painless injection higher in breastfeeding group than vapocoolant group 2) Vapocoolant spray reduced pain severity compared to no-treatment control group
Cohen 2009 USA (23)	4-6 y (n=57)	DPTaP, measles-mumps-rubella and inactive polio vaccine; 25-G 1 inch needle in thigh [3]	Vapocoolant (Ethyl Chloride) (n=31)	Soaked cotton ball (20 s)	No-treatment control (n=26)	Faces pain scale revised (child); Baseline distress VAS (parent and nurse); Immunisation distress VAS (parent and nurse);	No difference

						Observational distress (researcher)	
Cohen Reis 1997 USA (24)	4-6 y (n=62)	DTaP; IM; 26-G 1/2 inch needle in deltoid [1]	Vapocoolant (Fluori- Methane) spray + distraction (n=20)	Soaked cotton ball (15 s)	1) EMLA cream for 60min+distraction (blow on pinwheel) (n=21) 2) Distraction alone (control) (n=21)	Prior experience VAS (parent); Global mood scale (researcher); Observation scale of behaviour distress (researcher); Linear pain VAS (parent, nurse, researcher); Faces scale (child, parent, researcher, nurse); Cry duration (researcher); Parental distress VAS (parents own level of distress), Parental preference VAS (parents)	1) No difference 2) Vapocoolant reduced injection pain compared to control group for all measures except Global mood scale (researcher)
Ebner 1996 USA (20)	10-18 y (n=40)	Tetanus; Injection details NR [1]	Ice (n=NR)	Bag on injection site (15 mins)	No-treatment control (n=NR)	Faces Pain rating scale (child)	No difference
Eland 1981 USA (28)	4y9mo to 5y9mo (n=40)	DPT 0.5 ml; IM; 25-G 5/8 inch needle in vastus lateralis [1]	Frigiderm spray + cognitive information (n=10) OR Frigiderm + no cognitive information (n=10)	Directly to injection site (NR)	1) Aerosol air spray + cognitive information (n=10) 2) Aerosol air spray (n=10). Spray applied 3-5 s on the leg before vaccination	Colour assessment tool (child); Anxiety (parent and nurse)	1) Frigiderm spray reduced pain compared to air spray + cognitive information; 2) Frigiderm spray reduced pain compared to air spray
Gedaly-Duff 1992 USA (19)	4-6 y (n=38)	DPT (78%) or DT (22%); 25-G 5/8 inch needle (84%); deltoid (76%) [1]	Ice (n=19)	Bag on injection site (30 s)	No-treatment control (n=19)	Global mood scale (GMS) (observer); Radial pulse rate (observer); Oucher scale and Wong-Baker Faces scale (child)	No difference

Gupta 2017 India (26)	<3 mo (n=90)	wDPT; IM; 23-G 1 inch needle in anterolateral thigh [1]	Vapocoolant spray + breastfeeding (n=30)	Directly to injection site (2 s from 12 cm away)	1) EMLA cream 1g for 60 mins + breastfeeding (n=30) 2) Breastfeeding only (n=30)	Duration of first cry (observer); Latency of cry (observer); Modified Facial Coding Score (MFCS) (observer); Neonatal infant pain scale (observer)	1) Comparison not provided 2) VP+BF scores for MFCS and neonatal pain scale lower compared with breastfeeding only at 1 and 3 minutes post injection, no difference immediately post insertion
Luthy 2013 USA (17)	2-12 y (n=68)	Vaccine NR; injection details NR [1->4]	Vapocoolant spray (n=18)	Directly to injection site (3-7 s)	1) Distraction (DVD before, during, and after injection (n=27) 2) No-treatment control (n=22)	Wong-Baker FACES pain rating scale (parents); Anxiety (parents); Comparison with previous vaccination (parents); Preference for same treatment in future vaccinations (parents)	1) FACES pain scale and Anxiety: no difference 2) FACES pain scale and Anxiety: no difference
Maikler 1991 USA (27)	6-30 weeks (n=60)	DPT; IM; 25-G 5/8- inch needle in anterior thigh [1]	Frigiderm spray (dicholorotetra- fluorethane) (n=30)	Directly to injection site (2-3 s)	Compressed air spray (2-3 s directly to skin) (n=30)	Maximally Discriminative Facial Movement Coding System (MAX) (researcher); Cry type, latency and duration (researcher); Body movement, movement latency, number of movements, startle response and symmetry of movement (researcher)	Frigiderm spray reduced startle at needle insertion, increased cry latency and reduced movement symmetry compared to air spray

**ADULT
STUDIES**

Akcimen 2019 Turkey (18)	>18 y (n=292)	Tetanus 1 ml; IM; 25- G needle in deltoid [1]	1) Ice (n=107) 2) Vapocoolant spray (Nexcare® Coldhot) (n=90)	Ice: cube in latex glove (30 s); Vapocoolant: directly to injection site (10 s from 10 cm away)	No-treatment control (n=95)	Pain VAS (patient)	1) Ice reduced pain compared to control group 2) Vapocoolant reduced pain compared to control group
Mawhorter 2004 USA (2)	>18 y (n=185)	Varied travel vaccines; IM and SC; injection details NR [2-6]	Vapocoolant (Fluori- methane) (n=93)	Soaked cotton ball (15 s)	4°C saline via cotton ball prior to injection (n=92)	McGill present pain intensity (PPI) (patient)	Vapocoolant reduced immediate injection pain compared to untreated arm; effect not maintained at 5 minutes post injection
Taddio 2010 Canada (25)	Adults (n=352)	H1N1 virus vaccine 0.5mL, 22-G 1 inch needle in middle deltoid [1]	Vapocoolant spray (PainEase Medium spray) (n=88)	Directly to injection site within 60 s of injection (4-10 s)	1) 1–2 g of liposomal lidocaine 4% cream on injection site for 20–30 mins (n=88) 2) Nurse-directed tactile stimulation for 10 s before and during injection (n=88) 3) Self-directed distraction before and during injection (n=88)	Pain VAS (patient); Anxiety VAS (patient); Predicted pain VAS (patient); Global assessment of intervention (patient)	1) No difference 2) Comparison not provided 3) Comparison not provided

399 DPT = diphtheria, pertussis, tetanus; DTaP = diphtheria, tetanus, acellular pertussis; IM = intramuscular; NR = not reported; VAS = visual
400 analogue scale; wDPT = whole cell diphtheria, pertussis, tetanus.